Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.

Autor: Cole CB; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Morelli MP; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Fantini M; Precision Biologics, Inc, Bethesda, MD, USA. massimo.fantini@precision-biologics.com., Miettinen M; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Fetsch P; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Peer C; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Figg WD; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yin T; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Houston N; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., McCoy A; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lipkowitz S; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zimmer A; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lee JM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Pavelova M; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Villanueva EN; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Trewhitt K; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Solarz BB; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Fergusson M; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mavroukakis SA; Precision Biologics, Inc, Bethesda, MD, USA., Zaki A; Precision Biologics, Inc, Bethesda, MD, USA., Tsang KY; Precision Biologics, Inc, Bethesda, MD, USA., Arlen PM; Precision Biologics, Inc, Bethesda, MD, USA., Annunziata CM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. annunzic@mail.nih.gov.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Apr 26; Vol. 42 (1), pp. 102. Date of Electronic Publication: 2023 Apr 26.

SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling.

Autor: Shibuya Y; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.; Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Tohoku University School of Medicine, Miyagi 980-8574, Japan., Kudo K; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.; Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Tohoku University School of Medicine, Miyagi 980-8574, Japan., Zeligs KP; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.; Gynecologic Cancer Center of Excellence, Department of Obstetrics and Gynecology, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD 20814, USA.; Department of Obstetrics, Gynecology and Reproductive Science, Division of Gynecologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Anderson D; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.; Gynecologic Cancer Center of Excellence, Department of Obstetrics and Gynecology, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD 20814, USA., Hernandez L; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Ning F; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Cole CB; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Fergusson M; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Kedei N; Collaborative Protein Technology Resource, MD 20814, USA., Lyons J; Astex Pharmaceuticals, Cambridge, UK., Taylor J; Astex Pharmaceuticals, Pleasanton, CA 94588, USA., Korrapati S; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Annunziata CM; Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Publikováno v: Cancers [Cancers (Basel)] 2023 Feb 18; Vol. 15 (4). Date of Electronic Publication: 2023 Feb 18.

Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.

Autor: Green DS; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland.; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, Maryland., Ning F; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Duemler A; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Myers TG; Genomic Technologies Section, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, Maryland., Trewhitt K; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Ekwede I; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., McCoy A; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Houston N; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Lee JM; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Lipkowitz S; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Zimmer A; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Pavelova M; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Villanueva EN; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Smith L; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Blakely A; Surgical Oncology Program, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Casablanca Y; Gynecologic Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland., Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland., Stroncek DF; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland., Collins-Johnson N; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland., Panch S; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland., Procter J; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland., Pham C; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland., Korrapati S; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Holland SM; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland., Rosen LB; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland., Nunes AT; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Zoon KC; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, Maryland., Cole CB; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland., Annunziata CM; Women's Malignancies Branch, Center for Cancer Research (CCR), NCI, Bethesda, Maryland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jan 17; Vol. 29 (2), pp. 349-363.